Revolutionizing Neurology with Cutting-Edge Technology
NMTC is revolutionizing brain technology with its advanced ultra-thin electrodes that can interface with more neurons by reducing the size of the contacts. This breakthrough enables more precise communication within the brain, enhancing the potential for diagnosing and treating neurological disorders. Additionally, NMTC's technology offers a minimally invasive approach to back pain treatment, allowing a film electrode to be placed through a needle in the spine to stimulate broader areas without the need for incisions.
This cutting-edge technology is also a game-changer for pharmaceutical companies, as it enables the precise location of specific areas in the brain for the delivery of gene and cell-based therapies, while simultaneously monitoring their effects. No other technology on the market provides this level of precision.
NMTC will be presenting at a prominent pain meeting in late September, where Dr. Sean Li will showcase the technology, calling it "The Next Big Thing."
NMTC vs. Neuralink: A Real Contender in the Neurotech Race
While Elon Musk's Neuralink is making headlines for its bold vision, it’s NMTC that’s already FDA-cleared. Neuralink is still awaiting approval, while NMTC's technology is already in use at top academic hospitals across the U.S. And with Neuralink valued at a staggering $8 billion despite having no commercial revenue, NMTC—already generating revenue and establishing commercial deals—could be the true hidden gem in this space.
FDA-Approved and Commercially Deployed
NMTC's technology isn’t just a concept; it’s a reality that’s already improving patient outcomes. The company currently has three FDA-cleared products in use at some of the nation’s leading hospitals. In addition, NMTC has publicly announced plans to submit new applications for ablation technology to the FDA early next year. With revenue already flowing and a commercial agreement with a global medical device giant, NMTC is distinguishing itself from other neurotech startups still in their early stages.
Strategic Partnership with a $25 Billion Powerhouse
In 2020, NMTC forged a strategic partnership with Zimmer Biomet, a $25 billion market cap titan in the medical device industry. Zimmer Biomet is now distributing NMTC’s breakthrough diagnostic product for epilepsy, opening massive doors in the medical community. This partnership isn’t just a deal; it’s a game-changer.
Big Moves on the Horizon
NMTC isn’t slowing down. According to recent reports, a second distribution deal could be finalized in the very near future. Who the strategic is, has not been shared, but based on their previous partnership a strong contender could be Zimmer Biomet. And that’s not all—NMTC is also eyeing strategic partnerships for its drug delivery technology, which could lead to significant developments and additional catalysts in the near future.
Zimmer Biomet Could Make a Play to Acquire NMTC
As NMTC continues to explore distribution partnerships, Zimmer Biomet remains a potential candidate. If Zimmer becomes the distribution partner, an acquisition could also be on the table. Zimmer has a history of acquiring smaller medical device companies, and if NMTC continues its success, it’s only logical that Zimmer would want to bring this innovative company fully under its wing. Zimmer typically acquires between 2 and 8 companies annually—NMTC could be next. Additionally, the company is actively approaching strategic partners for its spinal cord stimulation electrode technology.
A Dream Team of Leadership and Advisors
NMTC’s leadership is world-class. CEO Dave Rosa brings deep experience from senior roles at major players like St. Jude Medical and Boston Scientific. Adding to the company’s credibility, the Mayo Clinic is a founding shareholder. NMTC’s advisors include some of the top neuroscientists from leading hospitals in the U.S., creating a powerhouse team driving the company forward.
Undervalued with Massive Upside
With just 34 million shares outstanding and a market cap of around $25 million as of September 2024, NMTC is vastly undervalued compared to its potential. With breakthrough technology, revenue generation, and upcoming catalysts, the stock could easily climb back to its all-time highs of $2-3 per share, offering a multi-bagger return from current levels. For context, Neuralink’s $8 billion valuation comes without any revenue—imagine what’s possible for NMTC.
The Federal Reserve Could Be the Wind at NMTC’s Back
As interest rate cuts loom in the latter half of the year, small-cap stocks like NMTC stand to benefit enormously. Lower rates could be a huge catalyst for stocks with imminent growth opportunities—making NMTC an interesting investment ahead of potential market shifts.
NMTC's Three Pillars: A Comprehensive Approach to Neurological Innovation
NMTC stands as a leader in three critical areas of medical innovation. First, the company specializes in brain-related diagnostic and ablation technologies, including products developed in partnership with Zimmer Biomet. Second, NMTC addresses chronic back pain through advanced percutaneous stimulation technologies, tapping into a $3-4 billion industry. Finally, the company's groundbreaking work in drug delivery enables precise treatment of neurological conditions, solidifying NMTC's position at the forefront of medical advancements.
